Clinical Trial Detail

NCT ID NCT04350463
Title A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene
Indications

lung small cell carcinoma

lung squamous cell carcinoma

Therapies

CC-90011 + Nivolumab

Age Groups: senior adult

No variant requirements are available.